As Gilead's Outlook Dims, Argus Downgrades
November 13, 2017 at 10:15 AM EST
Biotech stocks are given to high volatility, given several risks confronting the sector, namely FDA decisions, clinical trial results, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.